ERBB2 and breast cancer: IHC is a well-established method to allow subtyping of breast cancer in the clinical setting (luminal A, luminal B, ERBB2-overexpression, and basal-like) according to gene expression models, by using a four-marker panel (ER, PR, HER2, and Ki-67) [18].